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Abstract
Patients with bony and soft tissue sarcomas may require intensive treatment with chemotherapy and radiotherapy,
which often leads to a fall in haemoglobin levels, requiring blood transfusion. There may be advantages in
predicting which patients will require transfusion, partly because anaemia and hypoxia may worsen the response
of tumours to chemotherapy and radiotherapy. Between 1997 and 2003, a total of 26 patients who received intensive
treatment with curative intent were identified. Transfusions were given to maintain the haemoglobin at 10g/dl or
above during chemotherapy, and at 12 g/dl or above during radiotherapy. Eighteen (69%) required a transfusion, the
majority as a result of both the chemotherapy and RT criteria. There were 78 transfusion episodes, and 181 units of
blood given. In the 18 patients who required transfusion, the average number of units was 10.1, but seven patients
required more blood than this. The most significant factor influencing blood transfusion was choice of intensive
chemotherapy. Intensive chemotherapy and presenting Hb less than 11.6 g/dl identified 13 out of 18 patients who
needed transfusion. Adding a drop in haemoglobin of greater than 1.7 g/dl after one cycle of chemotherapy identified
16 out of 18 patients who required transfusion. The seven patients who had heavy transfusion requirements were
identified by age 32 or less, intensive chemotherapy and a presenting Hb of 12 g/dl or less. Erythropoietin might be a
useful alternative to transfusion in selected patient groups, especially those with heavy transfusion requirements.
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Introduction
Patients with bony and soft tissue sarcomas
may require intensive treatment with chemo-
therapy and radiotherapy, in addition to surgery.
Myelosuppressive chemotherapy frequently leads
to a fall in haemoglobin levels, requiring blood
transfusion. It is our policy to maintain the haemo-
globin greater than 10 g/dl for patients receiving
chemotherapy, in order to avoid symptoms of
anaemia with consequent reduction in activity and
quality of life [1–3]. There is also the possibility that
anaemia may impair tumour response to chemo-
therapy [4–8]. In addition, radiotherapy is known
to be more effective in the presence of oxygen
[9,10], and patients with lower haemoglobin levels
have been shown, in some tumour types, to have
lower rates of local tumour control [11–15]. It is
therefore our policy to maintain haemoglobin
levels greater than 12 g/dl for the duration of
radiotherapy.
The proportion of patients requiring transfu-
sion is difficult to establish, though it obviously
depends upon the tumour types included in
any series. For some patients who are identified
as requiring transfusion, it may be difficult to
schedule transfusion, particularly when this must
precede radiotherapy treatment. It is particularly
problematic for patients travelling long distances
to their Sarcoma Specialist Centre. The
possibility of predicting which patients would
require transfusion would therefore be attractive.
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This might also offer the possibility of preventative
treatment, for example with recombinant erythro-
poietin (EPO), with advantages to the patient and
the Blood Transfusion Service.
We therefore examined the transfusion needs
of our patients requiring intensive chemo- and
radiotherapy as part of their sarcoma management.
Patients and methods
Patients having combination chemotherapy and
radiotherapy (RT) were identified retrospectively
from our database. All patients receiving radical
treatment between 1997 and 2003 were included,
and a total of 26 patients were identified. The
diagnoses were classified into three categories,
firstly PNET (including Ewing’s sarcoma), secondly
osteo- and chondrosarcoma, and finally all other
sarcomas (Table I). There were 15 men and 11
women. The mean age of the patient population
was 35.5 years (median 31.0) and the ages ranged
from 16 to 70 years (Figure 1). One additional
patient received radiotherapy using a brachytherapy
implant inserted at the time of re-operation
prior to chemotherapy, and was excluded from the
study because of the timing of the radiotherapy
treatment.
The chemotherapy schedules varied according
to clinical indications and protocol changes during
the study period (Table II). Patients received
chemotherapy and radiotherapy in one of three
ways (Table III): nine patients received ‘sandwich’
treatment with chemotherapy stopping for the
duration of the RT and restarting afterwards; five
received RT and chemotherapy concurrently,
using a schedule based on the EICESS 92 and
EuroEwings 99, with the radiotherapy starting
after a minimum of two cycles of chemotherapy;
12 patients received radiotherapy after completion
of chemotherapy. In one of these 12 cases the inten-
tion had been to continue chemotherapy after
radiotherapy, but the patient was unable to tolerate
further chemotherapy due to uncontrollable nausea.
Blood transfusion requirements were noted,
including dates of transfusion and the total number
of units. The timing of transfusions was correlated
with the timing of the chemotherapy and radio-
therapy for the patient. Blood transfusions given as
Table I. Types of sarcoma treated.
Tumour
group categories
Number
of patients Total
PNET/Ewing’s 5 5
Osteosarcoma/
chondrosarcoma
Osteosarcoma 4
Chondrosarcoma 1 5
Soft tissue
Embryonal rhabdosarcoma 2
Alveolar rhabdosarcoma 2
Fibrosarcoma 1
Alveolar soft part sarcoma 1
Liposarcoma 1
Leiomyosarcoma 2
Epitheliod sarcoma 1
Synovial sarcoma 3
Malignant schwannoma 1
Malignant peripheral
nerve sheath tumour
1
NOS (not otherwise specified) 1 16
Total 26
Table II. Chemotherapy protocols used.
Protocol
Number
of patients
MMT 98: CEV/IVA/Cyclo/Etop/Carbo/VAC
(carboplatin, epirubicin, vincristine/ifosfamide,
vincristine, actinomycin D/
cyclophosphamide/etoposide/
carboplatin/vincristine, actinomycin D,
cyclophosphamide
1
PD (cis-platinum & doxorubicin) 4
VIDE (vincristine, ifosfamide
doxorubicin and etoposide)
3
EICESS 92: EVAIA (etoposide, vincristine,
doxorubicin, ifosfamide and actinomycin D)
3
EuroEwing 99: VIDE/VIA (vincristine,
ifosfamide, doxorubicin & etoposide/vincristine,
ifosfamide & actinomycin D)
2
VID (vincristine, ifosfamide and doxorubicin) 2
ID (ifosfamide & doxorubicin) 7
VIE (vincristine, ifosfamide and etoposide) 1
Carbo D (carboplatin & doxorubicin) 1
D (doxorubicin) 2
Table III. Timing of radiotherapy and chemotherapy.
Timing of RT and ChT Number of patients
‘Sandwich’* 9
Concurrent 5
RT given after chemotherapy 12
*Chemotherapy–RT–chemotherapy, one treatment following
the previous, with no overlap. RT and chemotherapy given on
same day.
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Figure 1. Age distribution of patients.
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a result of surgery are not included, because these
are so specifically related to site and surgical
techniques. Transfusions were given for two main
reasons: firstly, to maintain the haemoglobin at
10 g/dl or above during chemotherapy, and
secondly, to raise the haemoglobin level to 12 g/dl
or above prior to and during radiotherapy.
Results
Of the 26 patients in our series, 18 (69%) required a
transfusion during treatment (Table IV). The major-
ity required treatment as the result of both the
chemotherapy and RT criteria. Twelve patients
(46%) required transfusion for RT: in 11 cases, the
patients had already required transfusion because
of low haemoglobin during the preceding chemo-
therapy (Figure 2), and in only one was transfusion
required for RT alone. In this patient, the haemo-
globin level had remained stable and over 10 g/dl
during chemotherapy but was below 12 g/dl at the
start of RT.
There were 78 transfusion episodes, and 181 units
of blood given. Figure 3 shows the transfusion
requirements of the group. The average number
of transfused units of blood was 7.0 (standard devi-
ation (SD 7.2), and the average number of trans-
fusion episodes was 3.0 per patient (SD 3.1).
Considering only the 18 patients who required
transfusion, the average number of units required
was 10.1, and the average number of transfusion
episodes was 4.3. A heavy transfusion requirement
was defined as more than 10 units of blood.
There was clear evidence of variation in trans-
fusion need according to chemotherapy schedule,
with more intensive protocols requiring larger
amounts of blood (Figure 4). Of the 26 patients,
five received chemotherapy lasting more than
18 weeks (the equivalent of six cycles delivered
3-weekly); four of these had heavy transfusion
requirements, of more than 10 units of blood.
In two patients, a total of 24 and 25 units were
required to maintain haemoglobin at the appropriate
levels. The patient who required 24 units of blood
had an osteosarcoma treated with cis-platinum and
doxorubicin; there was no apparent reason for
this patient tolerating chemotherapy less well
than expected, though she was 32 at the time of
treatment. The 25-unit transfusion was required
by a patient with embryonal rhabdomyosarcoma,
who received high-dose therapy with peripheral
stem cell rescue. In addition to these two
Table IV. Timing of transfusions required.
Timing of transfusions
Number
of patients Total
Transfusion required
Only during RT 1
Only during ChT 6
During both RT and ChT 11 18 (69%)
No transfusion required 8 (31%)
Transfusion criteria were: for RT maintain Hb >12g/dl, and
for chemotherapy maintain Hb >10 g/dl. See text for further
details.
6
11 1
Total 26
Chemo RT
8
Figure 2. Venn diagram illustrating the transfusion requirements
in the study group of 26 patients.
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Figure 3. Frequency distribution of number of units of blood
required per patient.
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Figure 4. Frequency distribution of number of units of blood
required according to chemotherapy protocol. The abbreviations
are explained in Table II.
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patients, five others received greater than 10 units of
blood: three received cis-platinum as part of their
chemotherapy.
There was no relationship between age at
presentation and the need for transfusion, or
the number of units transfused. However, all the
patients who required heavy transfusion were
younger, 32 or less. There was no exact relationship
between sex and transfusion requirement, either
in general or amongst the heavy transfusion group
(more than 10 units of blood). Although more
units of blood were required by female patients
(mean 9.6 units per patient) than men (mean 5.0
units), this was not statistically significant (P 0.1).
However, the female patients on average had lower
presenting haemoglobin (mean 11.9 g/dl, range
9.2–13.9 g/dl) than the men (mean 13.5 g/dl, range
10.5–15.2 g/dl).
All seven of the heavy transfusion patients had
a presenting haemoglobin (Hb) of 12 or less g/dl.
Three other patients also had low Hb levels at
presentation, two of whom required no transfusion
at all. Twelve patients presented with a haemoglobin
level of 13 or more g/dl, and eight did require
a transfusion, though none had heavy transfusion
requirements.
A modest drop in haemoglobin of 1.7 g/dl or
less after the first cycle of chemotherapy identified
all eight patients who did not require blood. Seven
patients who did require blood also had drop
in haemoglobin of 1.7 g/dl or less after the first
cycle. Haemoglobin drop after two cycles did not
add additional discrimination of transfusion needs.
Different combinations of these factors were
examined, to assess whether transfusion needs
could be predicted. Combining the two factors of
intensive chemotherapy (defined as more than three
drugs or a regime containing cis-platinum) and
presenting Hb less than 11.6 g/dl identified 13 out
of 18 patients who needed transfusion. Adding
the third factor of a drop in haemoglobin of greater
than 1.7 g/dl after one cycle of chemotherapy
identified 16 out of 18 patients who required some
transfusion. Seven patients had heavy transfusion
requirements. The combination of age 32 or less,
intensive chemotherapy and presenting Hb of 12 g/dl
or less identified all seven patients, with no
false-positives.
Discussion
Patients with bony and soft tissue sarcomas
frequently require intensive chemotherapy, often
with radiotherapy added, as part of a multi-
disciplinary management strategy. The intensive
nature of the chemotherapy leads to myelosuppres-
sion, and anaemia is a frequent complication.
We investigated the scale of the transfusion require-
ments of our patients and found considerable
variation in the transfusion needs, which was
clearly associated with the intensity of the
chemotherapy schedule.
Predicting transfusion requirements
Just over two-thirds of patients required a trans-
fusion at some time during treatment and in these
patients the average number of units of blood
required was 10.1. A few patients required very
large quantities of blood transfusion, and in two,
24 and 25 units were required respectively. However,
one-third of patients did not require any transfusion.
Prediction of transfusion needs might help in
planning a patient’s treatment. This applies particu-
larly to the use of radiotherapy, which is more
effective in the presence of adequate tumour
oxygenation. In order to achieve the maximum
benefit from this treatment modality, it is advisable
to transfuse patients at least 48 h prior to radio-
therapy, and to maintain haemoglobin levels during
the radiotherapy course. Prediction of transfusion
needs for chemotherapy is also attractive, since
anaemia certainly affects quality of life [1–3].
There are also suggestions that low haemoglobin
levels are associated with lower efficacy from
chemotherapy [4–8].
The most significant predictor of blood trans-
fusion need was choice of chemotherapy, par-
ticularly the use of more than three drugs or a
regime containing cis-platinum (Figure 4). Intensive
chemotherapy and a presenting haemoglobin
less than 11.6 g/dl identified 13 out of 18 patients
who needed transfusion. Although five other
patients who needed transfusion were not identified,
these criteria are simple, and available at the time
of presentation.
All seven patients who had heavy transfusion
requirements were identified by a combination of
three factors available at presentation. The heavy
transfusion requirement in the younger patients was
almost certainly due to the use of more intensive
chemotherapy. There was no suggestion that the
sex of the patient influenced transfusion needs,
except that the average presenting haemoglobin
level was lower in women.
Anaemia, hypoxia and efficacy of cancer treatment
Health-related quality of life has been shown to
correlate directly with the severity of anaemia in
patients with cancer [3,16,17], and raising hae-
moglobin levels improves quality of life [3,18,19].
Some published work suggests that treat-
ment with erythropoietins has a positive effect
on quality of life [1,18,19], but the evidence is
inconclusive [20].
Anaemia is known to be an independent prog-
nostic factor for outcome in a number of tumour
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sites [11,13], including soft tissue sarcoma [15].
Tumour hypoxia is common in many tumour sites,
also including soft tissue sarcoma [9,14,15,21,22],
where survival is related to tumour oxygenation [15].
Hypoxia may facilitate malignant progression of
tumours [4, 10], and there is evidence of increas-
ing metastatic potential in the presence of hypoxia
in the laboratory [8] and in patients [21]. It has
also been suggested that tumour hypoxia in soft
tissue sarcomas is associated with more rapid cell
proliferation [22].
As well as the effects on quality of life, it has been
suggested that anaemia and hypoxia worsen the
response of tumours to chemotherapy [5–7] and
radiotherapy [7, 10]. Tumour resistance to radio-
therapy in anaemic patients can, at least partially, be
prevented or overcome by correction of anaemia,
resulting in better locoregional tumour control and
overall survival [7]. Although difficult to prove in
humans, there is experimental evidence in mice
that EPO restores the loss of radiosensivity asso-
ciated with anaemia [23]. Enhanced radiation
sensitivity has been demonstrated in tumours in the
laboratory as a result of correction of anaemia
resulting from chemotherapy [24].
There is good recent evidence, from double-
blind randomised trials, that recombinant human
EPO can improve haemoglobin levels in patients
having chemotherapy, for both solid [18,25] and
haematogenous cancers [26]. Other studies have
also shown that EPO can improve haemoglobin
levels in chemotherapy-induced anaemia, partic-
ularly at levels under or just over 10 g/dl [19,27].
EPO has also been reported to prevent chemo-
therapy-induced anaemia in patients with primary
malignant bone tumours [28]. Treatment with
EPO in patients receiving radiotherapy has been
shown to increment haemoglobin levels by approxi-
mately 0.7 g/dl per week in anaemic patients [12].
The same group have also demonstrated worse
outcome associated with anaemia, and a better
outcome in those patients whose anaemia reversed
rapidly with EPO treatment [12].
Haemoglobin can be maintained continuously
using EPO, or, in a stepwise manner, by intermittent
transfusion in response to falling haemoglobin
levels [29]. The first strategy produces a constant
satisfactory haemoglobin level, whilst the second
achieves only periodically acceptable levels. Given
the concerns that falling haemoglobin might cause
increased hypoxia, the maintenance of haemo-
globin through the use of erythropoietins has
theoretical advantages [29,30–32].
There have been concerns, for many years, that
blood transfusion may worsen outcome of patients
with cancer, perhaps by an immune suppression
mechanism [33,34]. Similar concerns have also
been raised regarding EPO treatment in patients
with breast [35] and head and neck cancer [36].
In contrast, survival advantage has also been
reported in patients treated with EPO [18,37]. It is
not entirely clear exactly why these differences in the
literature might exist, though there are methodo-
logical or data collection issues in some studies.
The evidence regarding survival and the use of EPO
is inconclusive at present [20].
Blood transfusion is also associated with signif-
icant side effects, including risk of administering
the wrong blood, infection, anaphylactic shock, iron
overload and thrombo-embolism. In one report 20%
of all transfusions were associated with side effects
[38]. In addition, the future of blood supplies in
the UK is threatened by a fall in the donor pool
due to an ageing population and increasingly
stringent safety criteria [39]. Clearly, prospective
trials of both treatments are needed urgently.
Costs of erythropoietins for treatment of anaemia
Using standard doses of erythropoietin, treat-
ment costs approximately £1000 per month.
If inadequate response is seen, doses may need to
be doubled, which doubles the cost. Attention must
also be paid to iron stores, which if low can inhibit
response to EPO [17]. By comparison, the cost
of transfusion is approximately £400 for a three
unit transfusion. A bed cost is difficult to estimate
and depends on the specific accounting procedures
used.
To look at the relative cost-effectiveness of EPO
in different groups of patients, we made a simple
cost comparison. In the patients who needed
heavy transfusion, there were 49 transfusion epi-
sodes. Assuming the cost of blood is £400 per
treatment episode, rather than £400 per three unit
transfusion, this gives a total cost for this sub-group
of £19 600. If this same group were treated with EPO
throughout their chemotherapy course, treatment
would be for a total of 46.5 patient months.
Assuming an approximate cost of £1000 per
month, this yields a total cost of £46 500. By this
simple calculation EPO would be 2.4 times as
expensive as transfusion. In comparison, taking
the whole group, there were 78 transfusion episodes,
and 136 months of chemotherapy. Using these
figures, the relative cost of EPO is 3.2 times the
cost of transfusion. Thus, the more cost-effective
group to treat with EPO would be those with heavy
transfusion requirements.
These calculations are very simple, and do not
take into account EPO dose modification that may
be necessary, including lowering or increasing dose
according to response. Since the cost of transfusion
has not included cost of admission to day unit or
for overnight stay, the relative difference between
EPO and transfusion will be less than these
simple calculations indicate. Particularly where
severe pressure exists on existing services, where
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capacity may not be adequate for progressively
increasing demand, non-financial considerations
may also be warranted. Reduction in the costs
of EPO would also alter this balance. In our
estimates, which are certainly over simple, EPO is
more expensive than blood transfusion by 2.4–3.2
times. In a study in which EPO was actually used
for treatment, a higher cost ratio of 3.9 was suggested
[41]. In a study of cost-effectiveness of recom-
binant human EPO (rHuEPO) in the prevention
of chemotherapy-induced anaemia, Barosi et al. [40]
estimated that the cost of rHuEPO was always
greater than $100 000 per quality-adjusted life year
(QALY). They concluded that according to current
use, rHuEPO is not cost-effective in the treatment
of chemotherapy-induced anaemia.
Further work is clearly needed to define more
precisely the roles of blood transfusion and EPO
treatment, particularly in relation to survival.
Reduction in the cost of erythropoietins would
clearly facilitate such work. As a result of this
study, we propose to follow patients during their
chemotherapy and to plan ahead for early blood
transfusion, in order to minimise haemoglobin
fall. We also propose to study in a prospective
manner how EPO might be used as a substitute for
blood transfusion.
Conclusions
The most significant predictor of blood transfusion
need was choice of chemotherapy. Intensive chemo-
therapy and a presenting haemoglobin less than
11.6 g/dl identified 13 out of 18 patients who
needed transfusion. The combination of younger
age, intensive chemotherapy and presenting Hb of
12 g/dl or less identified all seven patients who
required more than 10 units of blood.
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